Isoquinoline alkaloids

Other Names

Aporphine alkaloidsAporphinoid alkaloidsBenzo[c]phenanthridine alkaloidsBenzylisoquinoline alkaloidsBenzyltetrahydroisoquinoline alkaloidsBerbine alkaloidsBisbenzylisoquinoline alkaloidsEmetine alkaloidsIpecac alkaloidsIpecacuanha alkaloidsIsoquinoline alkaloidIsoquinoline derivativesIsoquinoline group alkaloidsIsoquinolinesIsoquinolinoid alkaloidsIsoquinolinoid marine alkaloidsMorphinan alkaloidsMorphine alkaloidsN-heterocyclic alkaloidsN-heterocyclic bioactive natural productsNarcotine alkaloidsOpium alkaloidsPavine alkaloidsPhenylalanine-derived alkaloidsPhthalideisoquinoline alkaloidsPlant alkaloids (isoquinoline type)Protoberberine alkaloidsProtopine alkaloidsSecondary plant metabolites (isoquinoline class)Simple isoquinoline alkaloidsSpirobenzylisoquinoline alkaloidsTetrahydroisoquinoline alkaloidsTyrosine- and phenylalanine-derived basesTyrosine-derived alkaloids

Synopsis

Isoquinoline Alkaloids: A Comprehensive Reference

1. Identity, Chemistry, and Natural Sources

1.1 Chemical Identity

Isoquinoline alkaloids are natural products of the group of alkaloids, which are chemically derived from isoquinoline. They form the largest group among the alkaloids. Considering the structures, this group can be divided into two major categories: simple isoquinolines, which are composed of a benzene ring fused to a pyridine ring, and benzylisoquinolines, which contain a second aromatic ring.

Isoquinoline alkaloids are a large family of phytochemicals found in a number of plants. They occur predominantly in families like Papaveraceae, Berberidaceae, and Ranunculaceae, and possess remarkable biological activities. Basically derived from phenylalanine and tyrosine, they are formed from the precursor 3,4-dihydroxytyramine (dopamine) via reaction with an aldehyde or ketone.

A total of about 2,500 isoquinoline alkaloids are known, which are mainly formed by plants. The isoquinoline alkaloids are primarily formed in the plant families of Papaveraceae, Berberidaceae, Menispermaceae, Fumariaceae, and Ranunculaceae.

1.2 Structural Subclasses

Based on varying levels of oxygenation, rearrangements at the intramolecular level, distribution, shared biosynthetic routes, and the presence of extra rings linked to the main moiety, isoquinoline alkaloids may be divided into 13 classes including benzyltetrahydroisoquinoline, benzylisoquinolines, aporphines, protoberberine, benzophenanthridine, phthalideisoquinoline, morphinans, pavines, cularines, bisbenzylisoquinolines (BBI), naphythylisoquinoline, promorphinans, and ipecac alkaloids. Interestingly, the primary precursor for biosynthesizing the other varieties of isoquinoline alkaloids in plants is the benzyltetrahydroisoquinoline type alkaloid.

Key representatives from clinically and pharmacologically important subclasses include:

Protoberberines: Berberine, palmatine, coptisine, jatrorrhizine, canadine (tetrahydroberberine)
Benzophenanthridines: Sanguinarine, chelerythrine
Morphinans: Morphine, codeine
Phthalideisoquinolines: Noscapine (narcotine), hydrastine, narceine
Aporphines: Boldine, glaucine, magnoflorine, bulbocapnine
Bisbenzylisoquinolines: Tetrandrine, dauricine
Ipecac alkaloids: Emetine, cephaeline

These include the narcotic analgesics morphine and codeine (morphinans), the muscle relaxant papaverine (1-benzylisoquinoline), the antimicrobial agents sanguinarine (benzophenanthridine) and berberine (protoberberine), the bronchodilator and anti-inflammatory glaucine (aporphine), and the potential anticancer drugs noscapine (phthalideisoquinoline) and dauricine (bisbenzylisoquinoline).

1.3 Natural Sources and Plant Families

Most of the isoquinoline alkaloids discovered to date have been derived from plants, such as Alangiaceae, Annonaceae, Berberidaceae, Fabaceae, Fumariaceae, Lauraceae, Menispermaceae, Papaveraceae, Ranunculaceae, and Rutaceae. Opium poppy (Papaver somniferum) is one of the oldest plant sources of commercial medicinal isoquinolines in the world.

Naturally occurring berberine, palmatine, and synthetic coralyne are the most widely distributed natural alkaloids in the isoquinoline family, and they are also the main active ingredients in some Chinese herbal medicines, such as Rhizoma coptidis and Cortex phellodendri. They are found in many plants, such as Chinese herb huanglian (Coptis chinensis), goldenseal (Hydrastis canadensis), Turkish berberis, and the roots of species belonging to the Malagasy genus Burasaia, Menispermaceae.

Major pharmacologically relevant components of Chelidonium majus (Greater Celandine), most of which were first isolated over a century ago, are isoquinoline alkaloids — berberine, chelerythrine, chelidonine, coptisine, sanguinarine.

In 2019, a new isoquinoline alkaloid, 6-methylisoquinoline, was identified from white button mushrooms (Agaricus bisporus). Beyond the plant kingdom, increasing numbers of isoquinoline alkaloids have been found in microorganisms, particularly in marine microorganisms.

1.4 Common Forms and Preparations

Isoquinoline alkaloids reach consumers and patients in a variety of forms depending on the specific compound:

Standardized herbal extracts: Powders, capsules, or tablets standardized to a specified percentage of a target alkaloid (e.g., berberine content in barberry root extract).
Isolated alkaloid salts: Berberine's current clinical use is often in the form of hydrochloride (i.e., BBR hydrochloride) or sulfate (i.e., BBR sulfate).
Traditional decoctions: Crude plant material (roots, stems, bark, rhizomes) prepared as water-based decoctions, the classical preparation in Traditional Chinese Medicine and Ayurveda.
Pharmaceutical preparations: Several isoquinoline alkaloids, including morphine, codeine, galantamine, and noscapine, are formulated as licensed pharmaceutical drugs.
Novel enhanced-bioavailability forms: Berberine is a natural alkaloid used to improve glycemia but displays poor bioavailability and increased rates of gastrointestinal distress at higher doses. Recently, dihydroberberine has been developed to combat these challenges.

2. Biosynthesis

Benzylisoquinoline alkaloids (BIAs) constitute a large class of plant specialized metabolites derived from tyrosine. The enantioselective condensation of dopamine (yielding the tetrahydroisoquinoline moiety) and 4-hydroxyphenylacetaldehyde (yielding the benzyl moiety) by norcoclaurine synthase (NCS) generates (S)-norcoclaurine, the common precursor to all BIAs. A variety of coupling reactions and functional group modifications establish a large number of structural subcategories and specific compounds with a plethora of pharmacological properties.

Biosynthetic pathways produce diverse BIA scaffolds: 1-benzylisoquinoline alkaloids (1-BIAs), bisbenzylisoquinoline alkaloids (bisBIAs), aporphine alkaloids (aporphines), morphinan alkaloids (morphinans), protopine alkaloids (protopines), protoberberine alkaloids (BBRs), benzo[c]phenanthridine alkaloids (BZPs), and phthalideisoquinoline alkaloids (PQs).

The most parsimonious explanation for the neuropharmacological properties of isoquinoline alkaloids is their ability to bind to dopaminergic and adrenergic receptors by virtue of their structural similarities with dopamine and noradrenaline.

3. Traditional and Historical Use

3.1 Overview

The use of plants containing isoquinoline alkaloids for therapeutic purposes dates to ancient times; many of those herbs constitute a fundamental part of the ethnobotany in different cultures around the world due to their medicinal, magic, and toxic uses. Mankind has long made use of plants containing isoquinoline alkaloids as active principles for medicinal and other purposes, and they have proved to be both a boon and a curse.

3.2 Opium Poppy (Papaver somniferum)

Vast archaeological evidence supports that Opium Poppy (Papaver somniferum) is one of the oldest herbal medicines used by humans for its analgesic properties. Since the first bioactive isoquinoline alkaloid, morphine, was isolated from the opium plant in the early 19th century, this compound class has attracted considerable scientific attention. In the 19th century, morphine was the first isoquinoline alkaloid isolated from Papaver somniferum. The plant's milky latex (opium) had been used by ancient Sumerians, Egyptians, and Greeks for pain relief and sedation long before morphine's isolation.

3.3 Traditional Chinese Medicine (TCM)

Berberine (黄连素, huáng lián sù) is a time-honored remedy in Traditional Chinese Medicine (TCM) that is found in various medicinal herbs and used to treat diabetes mellitus (DM), infections, diarrhea, and dysentery. Berberine, the major active component of Coptidis rhizome (黄连, huanglian), Phellodendri cortex (黄柏, huangbai), and Mahoniae caulis (亮叶十大功劳, Gong Lao Mu), exhibits several pharmacological activities, including antioxidant, anti-inflammatory, anti-apoptotic, cardioprotective, antineoplastic, antimicrobial, and antidiabetic effects.

Rhizoma Coptidis is an herb that has been frequently used in many traditional formulas for the treatment of diabetes mellitus (DM) over thousands of years. Isoquinoline alkaloids are the major bioactive ingredients of Corydalis. Eight types of alkaloids are found in Chinese Corydalis: protopine; PBB; phthalide; benzo-phenanthridine; aporphine; spirobenzylisoquinoline; benzylisoquinoline; and others.

Spirobenzylisoquinoline alkaloids are isoquinoline alkaloids with a unique 'spiro' structure. They have been found only within the plant family Fumariaceae, and more specifically within the genera Fumaria and Corydalis.

In traditional Chinese medicine (TCM), the roots, stems, leaves, and fruits of Nandina domestica are used for clearing away heat and dampness, relieving cough and resolving phlegm, which is applied to treat symptoms such as cold and fever, whooping cough, asthma, chronic bronchitis, etc.

3.4 Ayurvedic and South Asian Traditions

Traditional practice of Ayurveda in ancient India dates back to at least the first millennium BC. Berberis species (daruharidra) were employed in Ayurvedic formulations for jaundice, eye disorders, febrile illness, and skin conditions. The aqueous extract of Tinospora cordifolia contains isoquinoline alkaloids including palmatine and magnoflorine, which have been reported for insulin-mimicking and insulin-releasing effects.

3.5 Native American and European Herbalism

Inspired by the "signatura rerum" principle and an apparent ancient folk tradition, various indications were given for Chelidonium majus, such as anti-jaundice and cholagogue, pain-relieving, and quite often mentioned — ophthalmological problems. Central and Eastern European folk medicine has always been using this herb extensively.

A high content of berberine is found in the well-known Chinese drug (Huangliansu) taken to treat intestinal infections caused by Escherichia coli, Bacillus dysteriae, and other microorganisms. Native American healers used goldenseal (Hydrastis canadensis), a rich source of berberine and hydrastine, as a topical antiseptic and digestive tonic, and bloodroot (Sanguinaria canadensis), the source of sanguinarine, as an emetic and respiratory remedy.

3.6 Antirheumatic Use of Sinomenine

Sinomenine (SIN), an isoquinoline alkaloid, is isolated from the roots and stems of Sinomenium acutum or Caulis Sinomenii. Traditionally, sinomenine has been administered subcutaneously or orally as a decoction of the roots and stems of Sinomenium acutum. Its use for rheumatic and arthritic conditions has been part of the Chinese pharmacopoeia for centuries.

4. Key Constituents and Mechanisms of Action

4.1 Berberine (Protoberberine Subclass)

Berberine, an isoquinoline alkaloid, belongs to the class of protoberberine alkaloids. Antidiabetic effects of berberine are partly attributed to the activation of AMP-activated protein kinase (AMPK), which is a key mechanism and a potential treatment strategy for DM and its complications.

Berberine engages numerous signaling pathways, including the PI3K/Akt, NF-κB, AMPK, CREB, Nrf2, and MAPK pathways, to confer its neuroprotective effects. The neuroprotective mechanisms of BBR involve the inhibition of oxidative stress, mitochondrial dysfunction, inflammatory response, programmatic cell death (e.g., ferroptosis, necroptosis, and apoptosis), and the activation of autophagy.

The specific mechanisms underlying its antioxidant and anti-inflammatory effects may include: activation of endogenous antioxidant enzymes (SOD, CAT, GPx), stimulation of the AMPK, PI3K/AKT, and Nrf2 pathways, alleviation of oxidative stress, inhibition of NADPH oxidase, and reduction of ROS levels, thus preventing oxidative damage.

4.2 Sanguinarine (Benzophenanthridine Subclass)

Sanguinarine [13-methyl (1,3) benzodioxolo(5,6-c)-1,3-dioxolo (4,5) phenanthridinium] is a toxin that kills animal cells through its action on the Na⁺-K⁺-ATPase transmembrane protein. Sanguinarine has significant antifungal activity and possible use as a bio-fungicide for crop protection. Sanguinarine is also known for its DNA intercalation properties.

4.3 Morphine and Codeine (Morphinan Subclass)

The isoquinoline alkaloids include, most famously, the opiates morphine and codeine, as well as the antibiotic berberine. Morphine and codeine are two of the most important analgesics used in medicine, and plants remain the main commercial source of the alkaloids. Both compounds act as agonists at opioid receptors (primarily the µ-opioid receptor), producing analgesia, sedation, and at high doses, respiratory depression.

4.4 Galantamine (Amaryllidaceae Alkaloid)

Galantamine, an isoquinoline alkaloid isolated from the bulbs of Galanthus nivalis and widely distributed in the Amaryllidaceae family, is a reversible inhibitor of acetylcholinesterase (AChE) approved in 2001 for the treatment of Alzheimer's disease. Galantamine, a tertiary alkaloid, is a competitive and reversible inhibitor of acetylcholinesterase. While the precise mechanism of galantamine's action is unknown, it is postulated to exert its therapeutic effect by enhancing cholinergic function. This is accomplished by increasing the concentration of acetylcholine through reversible inhibition of its hydrolysis by cholinesterase.

4.5 Noscapine (Phthalideisoquinoline Subclass)

Noscapine is a phthalideisoquinoline alkaloid isolated from the Papaveraceae family including Papaver somniferum. It is known as a nonnarcotic opium derivative which constitutes 1%–10% of opium's alkaloid content and lacks any sedative, analgesic, excitatory, or respiratory depressant properties. For a long time, noscapine has been clinically used for treating cough. Noscapine has the potential to induce mitotic arrest and apoptosis in various cancer cells including thymic epithelial tumor, lymphoma, and breast carcinoma.

4.6 Sinomenine (Morphinan-type)

Sinomenine (SIN), an isoquinoline alkaloid, is isolated from the roots and stems of Sinomenium acutum or Caulis Sinomenii. Its chemical name is (9α, 13α, 14α)-7,8-dihydro-4-hydroxy-3,7-dimethoxy-17-methylmorpholinan-6-one. In preclinical models, sinomenine has demonstrated anti-inflammatory and neuroprotective properties.

4.7 DNA-Binding Properties Across the Class

Usually, isoquinoline alkaloids interact with DNA as intercalators, or they are arranged in a small groove; their external binding with phosphate groups is also possible. The putative anticancer alkaloids berberine, palmatine, jatrorrhizine, and sanguinarine are known to bind to nucleic acids. To develop them as potential drugs for therapeutic use, their binding affinity to functional proteins and mode of transport in the circulatory system need to be clearly understood.

5. Scientific Evidence by Area of Use

5.1 Metabolic Disorders: Type 2 Diabetes and Glycemia (Berberine)

Eight databases were searched for randomized controlled trials (RCTs) reporting clinical data regarding the use of berberine for the treatment of DM. Forty-six trials were assessed. Analysis of berberine applied alone or with standard diabetic therapies versus the control group revealed significant reductions in HbA1c (MD = −0.73; 95% CI (−0.97, −0.51)), FPG (MD = −0.86, 95% CI (−1.10, −0.62)), and 2hPG (MD = −1.26, 95% CI (−1.64, …)).

Fifty studies involving 4,150 participants were included in a 2024 meta-analysis. BBR alone significantly reduced fasting plasma glucose (FPG) (MD = −0.59 mmol/L, p = 0.048), 2-h postprandial blood glucose (2hPBG) (MD = −1.57 mmol/L, p < 0.01), LDL-C (MD = −0.30 mmol/L, p < 0.01), total cholesterol (TC) (MD = −0.30 mmol/L, p = 0.034), and triglycerides (TG) (MD = −0.35 mmol/L, p < 0.01). Current evidence suggests that BBR alone or in combination has significant potential for treating type 2 diabetes mellitus (T2DM).

Evidence strength: Moderate-to-strong for glycemic reduction based on multiple RCT meta-analyses, but many contributing trials are of variable quality with high heterogeneity (I² values often exceeding 90%), and the majority originate from a single ethnic population (Chinese subjects).

5.2 Dyslipidemia (Berberine)

Berberine was associated with significant reductions in total cholesterol (0.61 mmol/L), triglycerides (0.50 mmol/L), and LDL cholesterol (0.65 mmol/L) compared to the control group. In a meta-analysis of 16 clinical trials involving 2,147 patients with hyperlipidemia, berberine significantly reduced total cholesterol by 0.47 mmol/L, LDL cholesterol by 0.38 mmol/L, and triglycerides by 0.28 mmol/L. In those studies, patients' daily dose of berberine ranged 600–1,500 mg for 1–24 months. However, the authors noted that the majority of the studies were heterogeneous or had a high risk for bias and that additional, well-designed trials were needed to confirm the results.

The majority of evaluated articles consistently suggest that berberine has a beneficial effect on low-density lipoprotein (reductions ranging from approximately 20 to 50 mg/dL) and triglycerides (reductions ranging from approximately 25 to 55 mg/dL). In one study, 32 patients who were not receiving other lipid-lowering therapies were given berberine 500 mg twice daily for three months. Significant reductions in LDL, triglycerides, and total cholesterol were seen from baseline (25% reduction in LDL, 35% reduction in triglycerides, and 29% reduction in total cholesterol, P < .0001 for change from baseline).

Evidence strength: Moderate. Multiple RCTs report lipid-lowering effects, but high heterogeneity and predominantly Asian study populations limit generalizability. Larger, diverse, long-term trials are needed.

5.3 Inflammation (Berberine)

Pooled results of six clinical trials proved that berberine markedly lowered the CRP levels in patients with T2DM (SMD = −2.13, 95% CI (−2.98, −1.28), P < 0.05, I² = 96%). The IL-6 concentration in the trial group decreased by 1.83 (95% CI (−3.05, −0.61), P = 0.003; I² = 97%).

Evidence strength: Preliminary in clinical populations; extremely high I² values indicate substantial heterogeneity among the pooled trials. Mechanistic data are largely preclinical.

5.4 Neurological Conditions: Alzheimer's Disease (Galantamine)

Galantamine, an isoquinoline alkaloid approved in 2001 for the treatment of Alzheimer's disease, is used for the treatment of cognitive impairment in moderate and middle stages of the disease; however, it does not allow the slowing down or delaying of the neurodegenerative progression. Although the pharmacological action of galantamine yielded palliative results, its approval at the beginning of the 21st century marked a transition point in the development of therapeutic agents for Alzheimer's disease and prompted the study of other natural alkaloids for the treatment of complex neurodegenerative diseases.

There is no evidence that galantamine alters the course of the underlying dementing process. Galantamine is a well-established pharmaceutical with extensive RCT data supporting symptomatic benefit, and its regulatory approval represents the strongest clinical evidence of any isoquinoline alkaloid for a neurological indication.

5.5 Neuroprotection (Berberine — Preclinical and Early Clinical)

Berberine (BBR) exhibits neuroprotective qualities by inducing autophagy and facilitating the clearance of toxic aggregate proteins. BBR has been found to trigger autophagy in various cell types, including macrophages, lymphoblastic leukemia cells, retinal cells, and neuronal cells, as well as in various tissues such as the liver, lung, kidney, stomach, and breast.

Evidence strength: Almost entirely preclinical (cell culture and animal models) as of available literature. Human clinical trials specifically targeting neurodegenerative endpoints with berberine are limited and not yet sufficient for clinical conclusions.

5.6 Anticancer Activity

Isoquinoline alkaloid-enriched herbal plants have been used as traditional folk medicine for their anti-inflammatory, antimicrobial, and analgesic effects. They induce cell cycle arrest, apoptosis, and autophagy, leading to cell death. While the molecular mechanisms of these effects are not fully understood, it has been suggested that binding to nucleic acids or proteins, enzyme inhibition, and epigenetic modulation by isoquinoline alkaloids may play a role.

Berberine, an isoquinoline alkaloid, possesses anti-inflammatory, anti-diabetes, and anti-tumor properties. In the azoxymethane-initiated and dextran sulfate sodium (AOM/DSS)-promoted colorectal carcinogenesis mouse model, berberine-treated mice showed a 60% reduction in tumor number (P = 0.009).

Over 250 molecules with a broad range of bioactivities, including antitumor, antibacterial, cardioprotective, anti-inflammatory, neuroprotective and other activities, have been isolated and discussed.

Evidence strength: Predominantly in vitro and animal data for anticancer effects. No isoquinoline alkaloid supplement has received regulatory approval as an anticancer agent based on controlled human trial data, with the notable exception of lurbinectedin (a synthetic tetrahydroisoquinoline-derived drug) which has been approved for a specific oncology indication but is not sold as a dietary supplement.

5.7 Antimicrobial Activity

Isoquinoline alkaloids exhibit good antibacterial and antifungal activities. A high content of berberine is found in the well-known Chinese drug (Huangliansu) taken to treat intestinal infections caused by Escherichia coli, Bacillus dysteriae, and other microorganisms. Berberine exhibited antibacterial activity against Candida albicans with an MIC value of 75.53 μM. It affected the synthesis of membrane ergosterol and induced increased membrane permeability, causing loss of intracellular material to the outer space (DNA/protein leakage) as well as membrane disruption.

Evidence strength: Substantial in vitro evidence for antimicrobial activity. Clinical evidence in humans (outside of traditional use as a GI anti-infective in China) is limited and requires more rigorous RCT validation.

5.8 Antitussive Use (Noscapine)

Noscapine is a nonnarcotic opium derivative which constitutes 1%–10% of opium's alkaloid content and lacks sedative, analgesic, excitatory, or respiratory depressant properties. For a long time, noscapine has been clinically used for treating cough. Noscapine-based antitussive preparations represent one of the most established clinical applications of an isoquinoline alkaloid supplement beyond the classical opioids.

6. Body Systems and Health Areas

Endocrine/Metabolic System: Berberine — glycemic control, insulin sensitivity, AMPK activation, lipid-lowering.
Cardiovascular System: Berberine shows remarkable anti-inflammatory, antioxidant, antiapoptotic, and antiautophagic activity via the regulation of multiple signaling pathways, including AMPK, NF-κB, SIRT-1, HIF-1α.
Central Nervous System: Galantamine (acetylcholinesterase inhibition in Alzheimer's disease); berberine (preclinical neuroprotection); morphine and codeine (analgesia and cough suppression via opioid receptors).
Gastrointestinal System: Berberine — anti-infective and antidiarrheal use; noscapine — antitussive.
Immunological/Inflammatory System: Multiple isoquinoline alkaloids modulate NF-κB, COX-2, and cytokine pathways.
Oncology: Preclinical evidence for apoptosis, cell cycle arrest, and autophagy induction across multiple cancer cell types; no approved dietary supplement application.
Musculoskeletal System: Sinomenine — traditional use for rheumatism; preclinical anti-inflammatory data.
Respiratory System: Noscapine — antitussive; glaucine — bronchodilatory (aporphine subclass).

7. Dosage Forms and Dosages Reported in Studies

The following dosages are reported as stated in the cited sources and pertain primarily to the most studied alkaloid, berberine, as an illustrative example for the class. Other alkaloids are regulated as pharmaceuticals and their dosing is governed by regulatory agencies.

7.1 Berberine

Berberine supplements usually come as oral capsules, often in strengths of 400 mg or 500 mg. Product labels commonly advise one capsule by mouth 1 to 3 times daily with meals. Clinical studies have often used doses around 500 mg taken two or three times daily for up to three months, sometimes in combination with other medicines. Long-term safety data beyond a few months are limited, and higher doses may increase the risk of gastrointestinal side effects, low blood pressure, and heart rhythm changes.

In meta-analyzed trials involving hyperlipidemia, patients' daily dose of berberine ranged from 600–1,500 mg for 1–24 months.

After 2 weeks of berberine (300 mg, t.i.d., p.o.) administration, midazolam, omeprazole, dextromethorphan, losartan, and caffeine were used to evaluate enzyme activities of CYP3A4, 2C19, 2D6, 2C9, and CYP1A2, respectively — demonstrating that clinically meaningful CYP inhibition was seen at 300 mg three times daily (total 900 mg/day) in a crossover pharmacokinetic study.

7.2 Sinomenine

The usual dosage for injections is reported as 20 mg once daily with an increase of 10–15 mg every 3–4 days up to a maximum daily dose of 90–100 mg. For oral administration, the recommended intake has been reported as being anywhere from 30–120 mg/day in three divided doses to 180–300 mg/day in three divided doses.

7.3 Galantamine (Pharmaceutical)

The pharmacokinetics of galantamine are linear over a dose range of 8–32 mg/day. The clinical dose of galantamine is 16–24 mg/day.

8. Safety Considerations and Drug Interactions

8.1 General Toxicological Profile

Isoquinoline alkaloids include structurally similar sanguinarine, hydrastine, and berberine. Berberine has demonstrated cardiac and respiratory depression, smooth muscle contraction, and uterine contraction.

Sanguinarine is a toxin that kills animal cells through its action on the Na⁺-K⁺-ATPase transmembrane protein. Berberine, on the other hand, has been reported to cause cytotoxicity and adversely influence the synthesis of DNA.

A mass sanguinarine poisoning from the consumption of a Mexican prickly poppy (Argemone mexicana) resulted in gastrointestinal symptoms, hepatomegaly, anemia, skin darkening and lesions, erythema, and peripheral edema. On the severe end, affected individuals may experience ascites, congestive heart failure, and myocarditis.

Despite the toxicity and mutagenicity of sanguinarine and berberine, the compounds are still extensively studied due to the possibility of synthesis of derivatives with reduced toxicity. In optimized doses, these alkaloids could exhibit potential therapeutic effects with limited side effects.

8.2 Cytochrome P450 and Drug Transporter Inhibition

A decrease in CYP2D6 activity was observed as the 0–8 h urinary dextromethorphan/dextrorphan ratio increased ninefold (P < 0.01) after berberine administration. In addition, the losartan/E-3174 ratio doubled (P < 0.01), indicating a decrease in CYP2C9 activity. CYP3A4 activity was also inhibited, as the Cmax, AUC₀–∞, and AUC₀–₁₂ of midazolam were increased 38% (P < 0.05), 40% (P < 0.01), and 37% (P < 0.05) after BBR treatment, respectively.

This represents direct human clinical evidence that berberine meaningfully inhibits multiple CYP enzymes at doses used in supplementation. Berberine is a CYP3A4 inhibitor and a P-gp transporter substrate, and interaction studies have shown that coadministration of cyclosporine markedly elevates the blood concentration of cyclosporine. The increase in CyA bioavailability may be partly due to decreased metabolism because of CYP3A4 inhibition.

8.3 Interactions with Specific Drug Classes

Cyclosporine (immunosuppressant): Increased cyclosporine concentration has been reported in patients taking berberine. This interaction carries serious clinical implications for transplant patients.
Warfarin and anticoagulants: Warfarin is the clearest example among anticoagulants. Case reports and cohort analyses document changes in INR when berberine is started or stopped. Those changes can mean more bleeding or clotting risk.
Statins: Statins like atorvastatin and simvastatin are metabolized by CYP3A4. Berberine's inhibition of this enzyme could increase statin levels, potentially leading to a higher risk of muscle pain (myopathy) or liver damage.
Antidiabetic medications: If patients take metformin, sulfonylureas, insulin, or GLP-1 medications, adding berberine may increase the risk of low blood sugar or require closer monitoring.

8.4 Pregnancy and Neonatal Concerns

Berberine crosses the placenta and can displace bilirubin from albumin in fetal blood, a mechanism that can cause kernicterus (a type of brain injury in newborns caused by buildup of bilirubin). Berberine has demonstrated uterine contraction, providing an additional reason for caution in pregnancy. These safety signals were identified in pharmacological and toxicological research, not merely precautionary extrapolations.

8.5 Regulatory Status

In the UK, berberine is available over-the-counter as a food supplement regulated by the Food Standards Agency (FSA), not as a licensed medicine approved by the Medicines and Healthcare products Regulatory Agency (MHRA). Regulatory status varies by jurisdiction. In contrast, galantamine, morphine, codeine, and noscapine are licensed pharmaceutical products and not sold as dietary supplements in major markets.

8.6 Evidence Gaps and Limitations Across the Class

Plant-derived isoquinoline alkaloids comprise a vast source of multimodal agents with unique structural diversity, and a varied range of pharmacological activities. Complex diseases such as neurodegenerative disorders and cancer constitute a growing public health problem due to rising incidence and lack of effective therapies. Since pharmacotherapy based on a single target has been insufficient for drug development in complex diseases, the emerging multi-target approach is a promising strategy for the search of new drug candidates.

Despite hundreds of bioactive compounds in this class, the majority of pharmacological evidence remains preclinical. For most non-pharmaceutical members of this class (excluding berberine, galantamine, and noscapine), high-quality human RCT data are sparse. Increasing numbers of isoquinoline alkaloids have been isolated and identified from natural sources, and various studies have reported their antitumor, antimalarial, antibacterial, antifungal, antiparasitic and insecticidal, antiviral, anti-inflammatory, antiplatelet and other activities. As lead compounds in the drug discovery and development process, isoquinoline alkaloids have high probabilities of success, as reflected by several revolutionary drugs, such as the analgesic morphine, the antibacterial berberine, the antitussive codeine, the antirheumatic sinomenine, and the acetylcholinesterase inhibitor galanthamine.

References

Health Conditions

Health conditions that Isoquinoline alkaloids may help support.

No conditions available.

Body Systems

Body systems that Isoquinoline alkaloids may help support.

No body systems available.